TcPRF for Knee Osteoarthritis

Randomization and Blinding

• Randomization: Participants will be randomly assigned to one of two groups: PRF treatment or sham.
• Blinding: Both participants and investigators will be blinded to the treatment allocation. The device used for PRF treatment will have an identical appearance for both the active and sham groups, but the sham electrode will not deliver active treatment.

Intervention Both groups will receive disposable electrodes on either side of the knee: one skin electrode on the inside and one on the outside of the knee.

• PRF Group: Participants will receive PRF treatment using a specific protocol (e.g., 3 Hz, 5 ms, 15 minutes, 3 sessions with 1 week and 3 weeks interval). The output will be adjusted according to the distance between electrodes in cm. This will be between 0.7A (circumference 23cm) and 1.4A for 38cm (Spring 2, Clinical Guidelines, Table 1)
• Sham Group: Participants will receive a sham treatment using a device identical in appearance but without delivering the actual PRF therapy.

Outcome Measures Primary Outcome • Pain Reduction: Measured using the NRS (numerical rating scale) at baseline, immediately after treatment, and at follow-up intervals (2 weeks, 4 weeks, 8 weeks, 12 weeks).

Secondary Outcomes

• Functional Improvement: Assessed using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores.
• Patient Satisfaction: Measured using a Likert scale for overall satisfaction with treatment.
• Global Assessment: Patient's global assessment of change in pain and function.
• Medication reduction Sample Size Calculation
• Estimate: Based on previous studies and expected effect size, calculate the necessary sample size to achieve a power of 80% and a significance level of 0.05. The sample size must account for potential dropouts.

Data Collection and Management

• Data will be collected at baseline, post-treatment, and during follow-up visits.
• Use electronic case report forms (eCRFs) for data entry.
• Ensure the security and confidentiality of participant data. Statistical Analysis
• Primary Analysis: Compare the mean change in VAS scores between the PRF and sham groups using an independent t-test or ANCOVA, adjusting for baseline values.
• Secondary Analysis: Compare changes in WOMAC scores and patient satisfaction between groups using similar statistical methods.
• Responder Analysis: Define responders as those with ≥30% reduction in VAS scores from baseline and compare proportions between groups using a chi-square test.
• Intention-to-Treat (ITT) Analysis: Include all randomized participants in the analysis based on the treatment they were allocated, regardless of whether they completed the study.

Ethical Considerations

• Obtain informed consent from all participants.
• Ethical approval from a recognized Institutional Review Board (IRB) is required.
• Ensure that participants can withdraw at any time without affecting their standard care.

Monitoring and Safety

• Adverse Events: Monitor and record all adverse events during the study.
• Data Safety Monitoring Board (DSMB): Establish a DSMB to review safety data periodically.

Dissemination of Results

• Results will be published in a peer-reviewed journal and presented at relevant conferences within a year after results are known. Data will be reported according to CONSORT guidelines.

Timeline

• Recruitment Period: 3 months
• Intervention Period: 4 weeks
• Follow-up Period: 3 and 6 months
• Data Analysis and Reporting: 3 months after study completion.

Inclusion criteria

• Diagnosed with knee osteoarthritis according to NICE criteria.
• Chronic knee pain (Visual Analogue Scale [VAS] ≥ 4).
• Failure to respond adequately to conventional treatments (e.g., NSAIDs, physical therapy).
• Willingness to comply with study procedures. Exclusion Criteria
• Previous PRF/RF treatment for knee pain.
• Hyaluronic acid injection for knee pain in the past 6 months
• Knee surgery within the last 6 months.
• Severe cardiovascular, neurological, or psychiatric conditions.
• Active systemic infections or local skin infections at the knee.
• Pregnancy or lactation.